<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04826172</url>
  </required_header>
  <id_info>
    <org_study_id>IMB101-006</org_study_id>
    <nct_id>NCT04826172</nct_id>
  </id_info>
  <brief_title>Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease (IMPROVE-Ischemia)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imbria Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imbria Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of IMB-1018972 in subjects&#xD;
      with obstructive CAD and inducible ischemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of IMB-1018972 as measured by incidence and severity of treatment emergent AEs (including AEs leading to study drug discontinuation and AEs leading to death), as well as incidence of treatment emergent SAEs</measure>
    <time_frame>Randomization through Week 10 Safety Follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in number of ischemic segments during hyperemia (ischemia defined as absolute MBF ≤2.3 ml/kg/min) as measured by adenosine stress 15O-H2O PET</measure>
    <time_frame>Baseline through Week 8</time_frame>
    <description>Ischemia score defined on the basis of absolute hyperemic MBF as: (1) MBF 2.0-2.3 ml/g/min; (2) 1.7- 2.0 ml/g/min; (3) MBF &lt;1.7 ml/g/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total ischemia burden measured as ischemia score summed across all segments as measured by adenosine stress 15O-H2O PET</measure>
    <time_frame>Baseline through Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inducible perfusion defect expressed as % of myocardium as measured by adenosine stress 15O-H2O PET</measure>
    <time_frame>Baseline through Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Ischemia</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>IMB-1018972 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMB-1018972</intervention_name>
    <description>Modified release (MR) oral tablet</description>
    <arm_group_label>IMB-1018972 200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching oral tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented history of stable angina (CCS grading I-III) or anginal equivalent for ≥1&#xD;
             month prior to screening&#xD;
&#xD;
          -  Ability to safely abstain from beta blockers for 48 hours prior to echo examinations&#xD;
             in the opinion of the Investigator&#xD;
&#xD;
          -  Preserved LV systolic function, defined as LVEF≥50% by any imaging modality&#xD;
&#xD;
          -  Obstructive CAD and recent evidence of stress-induced myocardial ischemia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of childbearing potential or who are currently pregnant or breast-feeding&#xD;
&#xD;
          -  Clinically indicated for coronary revascularization (PCI/CABG) at time of screening or&#xD;
             clinically significant LMS or proximal LAD stenosis likely to warrant&#xD;
             revascularization during the study period in the opinion of the investigator.&#xD;
&#xD;
          -  Type 1 insulin dependent diabetes mellitus (IDDM)&#xD;
&#xD;
          -  Presence of pacemaker, cardiac resynchronization therapy and/or implantable&#xD;
             cardioverter defibrillator&#xD;
&#xD;
          -  Severe or clinically significant valvular heart disease&#xD;
&#xD;
          -  Clinically significant concurrent condition which could prevent the patient from&#xD;
             performing any of the protocol-specified assessments, represent a safety concern if&#xD;
             the patient participates in the trial or could confound trial assessments of safety or&#xD;
             tolerability&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Chamberlin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Imbria Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Jauregui</last_name>
    <phone>(617) 675-4060</phone>
    <email>Ischemia_ClinicalTrial@Imbria.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Imbria Investigational Site</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+45 78456260</phone>
      <email>Ischemia_ClinicalTrial@Imbria.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imbria Investigational Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35 8405106241</phone>
      <email>Ischemia_ClinicalTrial@Imbria.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imbria Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+46 (0)70 529 1121</phone>
      <email>Ischemia_ClinicalTrial@Imbria.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

